LAVA Therapeutics N.V.
NASDAQ:LVTX
1.77 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q3 | 2019 Q2 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 6.992 | 0.353 | 0.053 | 5.139 | 1.224 | 2.64 | 15.261 | 0.468 | 1.022 | 1.066 | 2.095 | 1.08 | 1 | 1.764 | 0.97 | 0.665 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.228 | 0 | 0.154 | 0.01 | 2.388 | 0.93 | 0 | 0 | 0 | 0 | 6.634 | 6.703 | 4.895 | 18.712 | 4.322 | 3.86 | 3.454 | 3.235 | 0 | 0 | 0 |
| Gross Profit
| -0.228 | 6.992 | 0.199 | 0.043 | 2.751 | 0.294 | 2.64 | 15.261 | 0.468 | 1.022 | -5.568 | -4.608 | -3.815 | -17.712 | -2.558 | -2.89 | -2.789 | -3.235 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 1 | 0.564 | 0.811 | 0.535 | 0.24 | 1 | 1 | 1 | 1 | -5.223 | -2.2 | -3.532 | -17.712 | -1.45 | -2.981 | -4.193 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 6.336 | 6.009 | 3.36 | 7.912 | 12.599 | 9.943 | 10.54 | 13.697 | 8.371 | 7.497 | 6.634 | 6.703 | 4.895 | 18.712 | 4.322 | 3.86 | 3.454 | 3.235 | 2.043 | 2.121 | 2.097 |
| General & Administrative Expenses
| 3.025 | 2.935 | 2.281 | 2.858 | 3.697 | 3.89 | 3.579 | 3.135 | 3.173 | 4.237 | 3.768 | 3.76 | 2.764 | 1.727 | 0.257 | 0.774 | 0.755 | 0.752 | 0.304 | 0.315 | 0.312 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3.025 | 2.935 | 2.281 | 2.858 | 3.697 | 3.89 | 3.579 | 3.135 | 3.173 | 4.237 | 3.768 | 3.76 | 2.764 | 1.727 | 0.257 | 0.774 | 0.755 | 0.752 | 0.304 | 0.315 | 0.312 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.698 | -4.876 | -4.823 |
| Operating Expenses
| 9.022 | 8.286 | 7.482 | 9.638 | 16.052 | 14.78 | 17.959 | 14.317 | 8.408 | 10.622 | 2.443 | 2.123 | 4.003 | 1.877 | 0.045 | 0.942 | 1.048 | 0.759 | -2.351 | -2.44 | -2.414 |
| Operating Income
| -9.361 | -1.952 | -5.442 | -10.727 | -13.545 | -13.539 | -11.479 | -1.571 | -11.076 | -10.712 | -9.336 | -8.368 | -6.579 | -19.439 | -2.815 | -3.664 | -3.544 | -3.986 | -2.351 | -2.44 | -2.414 |
| Operating Income Ratio
| 0 | -0.279 | -15.416 | -202.396 | -2.636 | -11.061 | -4.348 | -0.103 | -23.667 | -10.481 | -8.758 | -3.994 | -6.092 | -19.439 | -1.595 | -3.779 | -5.328 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.15 | 1.468 | -0.995 | 1.941 | 0.942 | -0.33 | -3.369 | 2.554 | 3.046 | 0.949 | 1.174 | 1.479 | -1.426 | -0.279 | 0.204 | -0.276 | -0.357 | -0.064 | -0.021 | -0.022 | -0.022 |
| Income Before Tax
| -8.211 | -0.484 | -6.437 | -8.786 | -12.603 | -13.869 | -14.848 | 0.983 | -8.03 | -9.763 | -8.162 | -6.889 | -8.005 | -19.718 | -2.61 | -3.94 | -3.902 | -4.05 | -2.373 | -2.463 | -2.436 |
| Income Before Tax Ratio
| 0 | -0.069 | -18.235 | -165.774 | -2.452 | -11.331 | -5.624 | 0.064 | -17.158 | -9.553 | -7.657 | -3.288 | -7.412 | -19.718 | -1.48 | -4.063 | -5.865 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.085 | 0.069 | 0.061 | 0.05 | 0.097 | 0.071 | 0.067 | 0.047 | 0.076 | 0.059 | 0.057 | 0.044 | 0.032 | 0.024 | 0.043 | 0 | 0.003 | 0.003 | 0.021 | 0.022 | 0.022 |
| Net Income
| -8.296 | -0.553 | -6.498 | -8.836 | -12.7 | -13.94 | -14.915 | 0.936 | -8.106 | -9.822 | -8.219 | -6.933 | -8.037 | -19.742 | -2.653 | -3.94 | -3.898 | -4.053 | -2.394 | -2.485 | -2.458 |
| Net Income Ratio
| 0 | -0.079 | -18.408 | -166.717 | -2.471 | -11.389 | -5.65 | 0.061 | -17.321 | -9.611 | -7.71 | -3.309 | -7.442 | -19.742 | -1.504 | -4.063 | -5.86 | 0 | 0 | 0 | 0 |
| EPS
| -0.31 | -0.021 | -0.24 | -0.34 | -0.48 | -0.53 | -0.57 | 0.036 | -0.31 | -0.38 | -0.32 | -0.27 | -0.31 | -12.14 | -9.44 | -9.37 | -8.71 | -9.06 | -0.131 | -0.136 | -0.135 |
| EPS Diluted
| -0.31 | -0.021 | -0.24 | -0.34 | -0.48 | -0.53 | -0.57 | 0.036 | -0.31 | -0.38 | -0.32 | -0.27 | -0.31 | -12.14 | -9.44 | -9.37 | -8.71 | -9.06 | -0.131 | -0.136 | -0.135 |
| EBITDA
| -9.241 | -1.808 | -5.259 | -10.575 | -13.393 | -13.41 | -11.29 | -1.466 | -10.967 | -10.611 | -9.24 | -8.281 | -6.502 | -19.368 | -2.767 | -3.601 | -3.494 | -3.946 | -2.288 | -2.374 | -2.348 |
| EBITDA Ratio
| 0 | -0.259 | -14.898 | -199.528 | -2.606 | -10.956 | -4.277 | -0.096 | -23.434 | -10.383 | -8.668 | -3.953 | -6.02 | -19.368 | -1.568 | -3.713 | -5.252 | 0 | 0 | 0 | 0 |